Medical/Pharmaceuticals

OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Sci...

2025-03-25 19:00 1967

3Shape Unveils Revolutionary TRIOS 6 Intraoral Scanner and TRIOS Dx Plus Diagnostic Software at IDS

COPENHAGEN, Denmark, March 25, 2025 /PRNewswire/ -- 3Shape today proudly introduces its revolutionary TRIOS 6 intraoral scanner, Diagnostic software - TRIOS Dx Plus*, and the DentalHealth patient app. The new TRIOS 6 intraoral scanner not only incorporates several new upgrades, including hypersp...

2025-03-25 18:51 2007

WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025

* Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY * Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY toRMB5,396.9 million * Added 151 new integrated projects, including 13 in late-stage and commercial stage ...

2025-03-25 18:30 2982

Rare loss-of-function variants in HECTD2 and AKAP11 confer a risk of bipolar disorder

Scientists at deCODE genetics, a subsidiary of Amgen, reveal today in Nature Genetics associations between rare loss-of-function variants in two genes and bipolar disorder. REYKJAVIK, Iceland, March 25, 2025 /PRNewswire/ -- Bipolar disorder is characterized by extreme mood swings, bouts of mania...

2025-03-25 18:00 2865

Medit Launches Medit i900 classic, a New Addition to Medit i900 Family Line Up

SEOUL, South Korea and NEWPORT BEACH, Calif., March 25, 2025 /PRNewswire/ -- Medit (www.medit.com ), a global leader in digital dentistry, is unveiling its latest scanner, the Mediti900 classic, as part of the Mediti900 Family. Launched on March 25, the Medit i900 classic p...

2025-03-25 15:00 3463

meerecompany enhances Korea-Vietnam medical exchange with Revo-i fellowship program

- Launch of SSC program to provide advanced robotic surgery training in Korea - Dr. Cao from Viet Tiep Friendship Hospital in Vietnam completed training at Severance Hospital SEOUL, South Korea, March 25, 2025 /PRNewswire/ -- meerecompany (CEO: Joon Koo Kim) announced today that its Revo-i surgi...

2025-03-25 10:00 2192

Exceptional Performance for Ureteral Stents: ICP DAS-BMP Reveals Latest TPU Materials at CMEF 2025

HSINCHU, March 25, 2025 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a committedTaiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is excited to announce its participation in CMEF (China International Medical Equipment Fair), held fromApril 8-11, 2025,...

2025-03-25 09:45 3242

Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY

SHANGHAI, March 24, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximatelyRMB5.7244 billion, representing an increase of 6.1% YoY. The net profit reachedRMB820.5 million, a 50.3% YoY growth, with a net pr...

2025-03-24 23:09 3556

Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY

SHANGHAI, March 24, 2025 /PRNewswire/ -- Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximatelyRMB5.7244 billion, representing an increase of 6.1% YoY. The net profit reachedRMB820.5 million, a 50.3% YoY growth, with a net pr...

2025-03-24 22:54 3613

WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024

* Revenue increased by 90.8% YoY to RMB 4,052 million * Gross profit grew by 121.6% YoY to RMB 1,240 million, with its margin of 30.6%, a 4.3 percentage points increase compared to that of 2023 * Net profit surged by 277.2% YoY to RMB 1,070 million, with its margin of 26.4%, a 13.0 percentag...

2025-03-24 22:45 3470

Sermonix and Regor Announce Strategic Collaboration to Optimize Regor's Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics

Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24, 2025 /PRNewswire/ -- Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically...

2025-03-24 22:30 1914

Alamar Biosciences Announces the Launch of the NULISAseq Mouse Panel 120

Providing the largest and most comprehensive, high sensitivity, protein biomarker analysis to advance pre-clinical research FREMONT, Calif., March 24, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announc...

2025-03-24 21:11 2231

Sungen Biomedical's world-first new drug SGC001 monoclonal antibody receives FDA fast track approval

NEW YORK, March 24, 2025 /PRNewswire/ -- On March 17, 2025, US time, the world's first acute myocardial infarction (AMI) antibody drug, SGC001, developed by Sungen Biomedical—an innovative biopharmaceutical company incubated by Beijing Hotgen Biotech Co., Ltd. (SH.688068)—received Fast Track Des...

2025-03-24 21:00 1718

Ractigen's RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data Presented at EAU 2025

NANTONG, China and MELBOURNE, Australia, March 24, 2025 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today announced the presentation of positive preliminary data from its ongoing Phase I clinical trial of ...

2025-03-24 20:30 2816

SineuGene Therapeutics Announces FDA IND Clearance for SNUG01, a First-in-Class TRIM72-Targeted Gene Therapy for ALS

BEIJING, March 24, 2025 /PRNewswire/ -- SineuGene Therapeutics Co., Ltd. ("SineuGene"), a clinical-stage biotech company pioneering innovative therapies for neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) appl...

2025-03-24 20:00 3391

English Version of "Long-term Care Tech Portal" Newly Launched, Introducing Latest Care and Age Tech in Japan

TOKYO, March 24, 2025 /PRNewswire/ -- The long-term care robot portal site management office released the English version of the "Long-term Care Tech Portal" (https://robotcare.jp/en/home/index?type=pw ), a portal site providing information on state-of...

2025-03-24 15:00 2386

Fangzhou Inc. Reports Strong Growth in 2024 Annual Results: 11.2% Revenue Growth and 139% Year-on-Year Increase in Adjusted Net Profit Driven by AI-Powered Innovation

HONG KONG, March 23, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced on March 21st, 2025 its financial results for fiscal year 2024, reporting total revenue ofRMB 2.7 billion, representing an 11.2% year-over-year inc...

2025-03-24 11:00 3082

GSK's Omjjara (momelotinib) approved in Singapore as the first treatment indicated for myelofibrosis patients with anaemia

* Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ruxolitinib * Nearly all myelofibrosis patients globally are estimated to develop anaemia over the course of the disease, and over 30% will discontinue treatment due to ...

2025-03-24 10:00 2140

ArkBio Announces the Completion of Phase III Clinical Study for AK0901 in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in China

SHANGHAI, March 24, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of attention deficit hyperactivity disorder (ADHD). This milestone represents a substant...

2025-03-24 09:00 3104

CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer

SUZHOU, China, March 23, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation application to the European Medicines Agency (EMA) for sugemalimab. T...

2025-03-24 08:15 2686
1 ... 115116117118119120121 ... 644